For the year ending 2025-12-31, ALNY made $3,713,937K in revenue. $328,168K in net income. Net profit margin of 8.84%.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Total revenues | 3,713,937 | |||
| Cost of goods sold | 677,166 | |||
| Cost of collaborations and royalties | 4,705 | |||
| Research and development | 1,319,775 | |||
| Selling, general and administrative | 1,210,713 | |||
| Total operating costs and expenses | 3,212,359 | |||
| Income (loss) from operations | 501,578 | |||
| Interest expense | 252,627 | |||
| Interest income | 111,470 | |||
| Loss related to convertible debt | 42,473 | |||
| Other income (expense), net | 5,204 | |||
| Total other expense, net | -178,426 | |||
| Income (loss) before income taxes | 323,152 | |||
| (provision for) benefit from income taxes | 9,405 | |||
| Net income (loss) | 313,747 | |||
| Unrealized gains (losses) on marketable securities | 1,816 | |||
| Foreign currency translation gains (losses) | 11,624 | |||
| Defined benefit pension plans, net of tax | -981 | |||
| Net other comprehensive loss | 14,421 | |||
| Comprehensive income (loss) | 328,168 | |||
| Net income (loss) per common share, basic (in dollars per share) | 2.39 | |||
| Net income (loss) per common share, diluted (in dollars per share) | 2.33 | |||
| Weighted average common shares, basic (in shares) | 131,004,000 | |||
| Weighted average common shares, diluted (in shares) | 134,684,000 | |||
ALNYLAM PHARMACEUTICALS, INC. (ALNY)
ALNYLAM PHARMACEUTICALS, INC. (ALNY)